Introduction
============

Chronic lymphocytic leukemia (CLL), a common type of chronic B-cell lymphoproliferative disorders (B-CLPD), seriously harms human health. To date, the etiology of CLL remains unclear, and hereditary factors as well as physical and chemical factors may contribute to the development and progression of this disease. Previous studies demonstrated that chronic inflammation was an enabling characteristic of cancer, and unexceptionally, it played an important role during the course of CLL \[[@b1-crt-2018-358]-[@b3-crt-2018-358]\].

Serum albumin, an important protein synthesized in liver, is not only an indicator of nutrition supply, but also a marker of inflammatory state. During the process of inflammation, albumin decomposes rapidly and therefore, low content of serum albumin is associated with poor prognosis in many diseases, such as non-small cell lung cancer (NSCLC), prostate cancer and CLL \[[@b4-crt-2018-358]-[@b7-crt-2018-358]\]. Like serum albumin, fibrinogen is also a marker of inflammation. Previous studies demonstrated that elevated fibrinogen level represented an inferior overall survival (OS) in esophageal carcinoma, NSCLC, prostate cancer, gallbladder cancer and so on \[[@b6-crt-2018-358],[@b8-crt-2018-358]-[@b10-crt-2018-358]\]. Albumin-to-fibrinogen ratio (AFR) is a novel immune biomarker to predict prognosis. Previous research showed that in NSCLC, low level of AFR represented an adverse OS, and both time-dependent receiver operating characteristic curve and multivariate Cox regression analysis indicated AFR was a superior prognostic marker when comparing with serum albumin and fibrinogen \[[@b11-crt-2018-358]\].

So far, there have been a lot of biomarkers related to molecular biology and cytogenetics, such as tumor protein 53 (*TP53*) and immunoglobulin heavy variable-region gene (*IGHV*) mutation status, to predict survival of CLL patients. However, immune indices which can effectively evaluate the prognosis of CLL patients remain absent. The prognostic value of AFR in CLL was not reported previously. Whether AFR has the same value to predict survival in CLL as in NSCLC needs further verification. We retrospectively investigated the correlations of AFR with other clinical factors, and examined the impact of AFR level on survival in 191 untreated CLL individuals in order to evaluate whether AFR level could independently predict prognosis.

Materials and Methods
=====================

1. Patients
-----------

Totally 191 previously untreated CLL patients diagnosed from June 1995 to November 2017 in our hospital were enrolled in this single-center retrospective study. Diagnosis of CLL was based on the International Workshop on CLL-National Cancer Institute criteria.

2. Data collection
------------------

Laboratorial data such as absolute lymphocyte count, absolute platelet count, hemoglobin, β2-microglobulin (β2-MG), serum albumin and fibrinogen were accessible from the hospital-based laboratory service within 24 hours after first admission.

Detection of *TP53* mutation and *IGHV* mutation status were performed as previously described \[[@b12-crt-2018-358]\]. A germline homology of 98% as a cut-off value was used to differentiate *IGHV* mutated from unmutated cases.

Fluorescence *in situ* hybridization was carried out to detect *TP53* deletion according to the procedures described previously \[[@b13-crt-2018-358]\]. CD38 and ZAP-70 were detected via flow cytometry, and the cut-off value for positivity were 30% and 20%, respectively.

3. Statistical analyses
-----------------------

Cut-off value was determined by use of X-tile \[[@b14-crt-2018-358]\], a software that allows the user to move a cursor across the grid to test multiple divisions and accept the best p-value. SPSS ver. 23 (IBM Corp., Armonk, NY) was used to analyze data. OS was defined as time from diagnosis to death or last follow-up and treatment-free survival (TFS) was calculated as time between diagnosis and first-line treatment. Survival curves were constructed by Kaplan-Meier method and log-rank test was used for statistic associations. Comparisons of AFR as continuous parameter in different groups were described using unpaired t test for unpaired samples. The Cox proportional hazards model was established to evaluate factors (including AFR level) at diagnosis on survival by univariate and multivariate analyses. For the multivariate analysis, we included variables whose p-value is less than 0.05 during the univariate analysis. p \< 0.05 was defined as statistical significance.

4. Ethical statement
--------------------

The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. Subjects provided written informed consent and carried out according to the Declaration of Helsinki.

Results
=======

1. Patient characteristics
--------------------------

Totally 191 previously untreated CLL patients were involved in our study, and their baseline characteristics were showed in [Table 1](#t1-crt-2018-358){ref-type="table"}. Median age was 61 years old (range, 23 to 86 years) and the ratio of male/female was 2.0. There were 76 patients in Binet A stage (39.8%), and 115 patients in Binet B or C stage (60.2%). The number of patients with *TP53* disruption and unmutated *IGHV*were 43 (22.5%) and 77 (40.3%), respectively. Median follow-up was 51 months (range, 1 to 270 months). Totally 124 patients (64.9%) received treatment including immunochemotherapy (109/124, 87.9%), ibrutinib (4/124, 3.2%), and data not available (11/124, 8.9%).

At diagnosis, median value of albumin was 42 g/L (range, 21.0 to 53.7 g/L), and median value of fibrinogen was 2.49 g/L (range, 0.56 to 12.05 g/L). Median value of AFR at diagnosis was 17.19 (range, 2.85 to 79.46 g/L), and the cut-off point of AFR according to the analysis of X-tile yielded the highest difference in OS was 9.70. The numbers of patients whose AFR ≤ 9.70 (low level) and \> 9.70 (high level) were 20 and 171, respectively.

2. Correlations between the AFR value and the other factors
-----------------------------------------------------------

Correlations between the AFR value and the other factors were presented in [Table 1](#t1-crt-2018-358){ref-type="table"}. Patients who were more than 65 years old had lower AFR than young patients (p \< 0.001).

3. Prognostic impact of AFR and clinical outcome
------------------------------------------------

The OS of patients with low AFR was inferior to that of patients with high AFR (p \< 0.001) ([Fig. 1B](#f1-crt-2018-358){ref-type="fig"}). The 3- and 5-year OS was 56.1% and 56.1% in low AFR group vs. 92.8% and 82.4% in high AFR group. However, there was no significant difference of TFS between two groups (p=0.415) ([Fig. 1A](#f1-crt-2018-358){ref-type="fig"}).

Univariate Cox regression analysis showed that Binet ≥ stage B (p \< 0.001), β2-MG \> 3.5 mg/L (p \< 0.001), CD38-positive \> 30% (p=0.048), *TP53* disruption (p=0.020), and unmutated *IGHV* (p=0.045) had adverse effects on TFS ([Table 2](#t2-crt-2018-358){ref-type="table"}). In addition, age \> 65 years old (p=0.007), β2-MG \> 3.5 mg/L (p=0.032), *TP53* disruption (p \< 0.001), unmutated *IGHV* (p=0.001), and AFR ≤ 9.7 (p=0.001) were associated with inferior OS ([Table 3](#t3-crt-2018-358){ref-type="table"}). Multivariate Cox regression analysis demonstrated that Binet ≥ stage B (p=0.002) and β2-MG \> 3.5 mg/L (p \< 0.001) were independent risk factors for TFS and age \> 65 years (p=0.013), *TP53* disruption (p=0.008), unmutated *IGHV* (p=0.014), and AFR ≤ 9.7 (p=0.003) could independently had negative impact on OS.

4. Subgroup analysis of AFR
---------------------------

Totally 191 CLL patients were divided into subgroups according to risk factors in CLL international prognostic index (CLL-IPI). Worse OS was seen in individuals with low AFR in subgroups such as age \> 65 years old (p=0.001) ([Fig. 2A](#f2-crt-2018-358){ref-type="fig"}), unmutated *IGHV* (p=0.001) ([Fig. 2B](#f2-crt-2018-358){ref-type="fig"}), mutated *IGHV* (p=0.034) ([Fig. 2B](#f2-crt-2018-358){ref-type="fig"}), Binet B/C (p=0.003) ([Fig. 2C](#f2-crt-2018-358){ref-type="fig"}), *TP53* disruption (p \< 0.001) ([Fig. 2D](#f2-crt-2018-358){ref-type="fig"}), and β2-MG ≤ 3.5 mg/L (p \< 0.001) ([Fig. 2E](#f2-crt-2018-358){ref-type="fig"}).

Discussion
==========

CLL is one of the most frequent type of B-CLPD. It is well known that microenvironment plays a significant role in the development of CLL and chronic inflammation is mainly involved in this process. It is known to all that the amount of circulating immune cells such as monocytes can affect survival of CLL patients \[[@b15-crt-2018-358]\]. Proteins such as albumin and fibrinogen are indictors of chronic inflammation and nutrition, and may be a useful marker for prediction of CLL patients' survival. Previous study revealed that AFR could effectively predict prognosis in NSCLC individuals. However, whether AFR has promising prognostic value in CLL patients remains unclear. In this retrospective study, we analyzed the clinical factors and prognosis of 191 untreated CLL patients with different levels of AFR. Patients who were more than 65 years old had lower AFR than young patients. In addition, although it had no statistic difference, it had a tendency that patients with high concentration of β2-MG or *TP53* disruption frequently had low AFR because β2-MG was also a sensitive biomarker for inflammation \[[@b16-crt-2018-358]\] and chronic inflammation can be initiated when tumor suppressor gene *TP53* disruption \[[@b17-crt-2018-358]\]. Besides, the high level of β2-MG and *TP53* disruption were clinically related with the inferior prognosis of patients with CLL, and patients with poor prognosis usually hardly survived due to various clinical factors, such as nutrition, organ function, biosynthesis ability and etc., which were strongly related with the content of albumin and fibrinogen. These might account for the relationship between AFR level and β2-MG level or *TP53* disruption.

We found that low AFR was an adverse prognostic biomarker for OS, no matter what other adverse prognostic factors they had, raising the possibility that severe inflammation might accelerate and exacerbate the development of CLL. Subgroup analyses showed significant differences of different levels of AFR for OS in patients with age \> 65 years old, unmutated *IGHV*, mutated *IGHV*, Binet B/C, *TP53* disruption, and β2-MG ≤ 3.5 mg/L, which demonstrated that AFR level could optimize the prognostic stratification based on CLL-IPI and should be included in the CLL-IPI prognosis model. Other analyses through different validation sets in different methods, such as prospective observation or interventional studies were strongly recommended in order to validate feasibility of adding AFR level into CLL-IPI. In addition, Cox regression analysis also revealed that low AFR level could predict an inferior OS and was independent of factors involved in CLL-IPI and other prognostic markers such as CD38 and ZAP-70.

Why AFR decreased in CLL might be accounted for the following reasons. Serum interleukin 6 and tumor necrosis factor α were in high level in CLL patients, and these two cytokines were adverse markers in CLL and would downregulate the synthesis of albumin \[[@b18-crt-2018-358]-[@b20-crt-2018-358]\]. In addition, circulating fibroblast growth factor-2 and vascular endothelial growth factor were elevated in CLL patients, and these two proteins, whose serum concentrations were high in patients with advanced diseases, could promote the synthesis of fibrinogen \[[@b21-crt-2018-358],[@b22-crt-2018-358]\]. Additionally, when patients were undernourished, both levels of albumin and fibrinogen would decline. However, when chronic inflammation disturbed patients, albumin was reduced while fibrinogen was elevated. Based on this, AFR might be a better biomarker to predict prognosis than single albumin or fibrinogen because ratio could effectively remove nutritional factors and amplify the effects of inflammation.

In summary, we retrospectively explored clinical features and prognostic value of AFR in 191 untreated CLL patients. Low level of AFR was more common in CLL patients who were more than 65 years old. In addition, low AFR level was associated with poor prognosis regardless of other clinical factors and AFR level was an independent prognostic factor for OS. AFR level could also predict the survival of patients stratified according to the biomarkers in CLL-IPI. Further researches containing a larger population and multicenter data are needed to better understand the roles of AFR level in CLL.
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###### 

Baseline characteristics of 191 untreated chronic lymphocytic leukemia patients

  Parameter               No. of cases (%)   AFR (mean±SD)   p-value
  ----------------------- ------------------ --------------- ----------
  **Age (yr)**                                               
   \> 65                  66 (34.6)          15.01±5.20      \< 0.001
   ≤ 65                   125 (65.4)         18.86±7.82      
  **Sex**                                                    
   Male                   128 (67.0)         17.22±6.04      0.399
   Female                 63 (33.0)          18.16±9.25      
  **Binet stage**                                            
   A                      76 (39.8)          17.46±5.55      0.913
   B or C                 115 (60.2)         17.58±8.21      
  **CD38 (\> 30%)**                                          
   Positive               41 (21.5)          17.93±5.47      0.692
   Negative               150 (78.5)         17.42±7.68      
  **ZAP-70 (\> 20%)**                                        
   Positive               86 (45.0)          17.87±5.49      0.555
   Negative               105 (55.0)         17.25±8.44      
  **β2-MG (mg/L)**                                           
   \> 3.5                 82 (42.9)          16.40±6.17      0.061
   ≤ 3.5                  109 (57.1)         18.38±7.89      
  ***TP53* disruption**                                      
   Yes                    43 (22.5)          15.74±5.14      0.066
   No                     148 (77.5)         18.05±7.69      
  ***IGHV* mutation**                                        
   Yes                    114 (59.7)         16.84±5.54      0.112
   No                     77 (40.3)          18.54±9.17      

AFR, albumin-to-fibrinogen ratio; SD, standard deviation; β2-MG, β2-microglobulin; *TP53*, tumor protein 53; *IGHV*, immunoglobulin heavy variable-region.

###### 

Univariable and multivariate analysis of treatment-free survival in 191 patients with chronic lymphocytic leukemia

  Characteristic      Univariate analysis   Multivariate analysis                                                           
  ------------------- --------------------- --------------------------------------------------------- --------------------- ---------------------------------------------------------
  Age \> 65 yr        1.089 (0.757-1.568)   0.645                                                     ND                    ND
  Binet ≥ stage B     2.747 (1.836-4.110)   \< 0.001^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^   2.012 (1.302-3.109)   0.002^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^
  β2-MG \> 3.5 mg/L   2.734 (1.904-3.927)   \< 0.001^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^   2.023 (1.367-2.993)   \< 0.001^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^
  CD38 (\> 30%)       1.507 (1.003-2.262)   0.048^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^      1.274 (0.837-1.939)   0.259
  ZAP-70 (\> 20%)     1.168 (0.819-1.668)   0.391                                                     ND                    ND
  *TP53* disruption   1.633 (1.079-2.471)   0.020^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^      1.237 (0.799-1.916)   0.339
  *IGHV* unmutated    1.439 (1.009-2.052)   0.045^[a)](#tfn1-crt-2018-358){ref-type="table-fn"}^      1.038 (0.709-1.519)   0.848
  AFR ≤ 9.7           1.237 (0.720-2.126)   0.440                                                     ND                    ND

HR, hazard ratio; CI, confidence interval; ND, not done; β2-MG, β2-microglobulin; *TP53*, tumor protein 53; *IGHV*, immunoglobulin heavy variable-region; AFR, albumin-to-fibrinogen ratio.

Statistically significant.

###### 

Univariable and multivariate analysis of overall survival in 191 patients with chronic lymphocytic leukemia

  Characteristic      Univariate analysis   Multivariate analysis                                                           
  ------------------- --------------------- --------------------------------------------------------- --------------------- ------------------------------------------------------
  Age \> 65 yr        2.589 (1.296-5.174)   0.007^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^      2.456 (1.206-5.000)   0.013^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^
  Binet ≥ stage B     2.126 (0.981-4.607)   0.056                                                     ND                    ND
  β2-MG \> 3.5 mg/L   2.153 (1.070-4.332)   0.032^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^      0.835 (0.386-1.805)   0.646
  CD38 (\> 30%)       1.003 (0.385-2.614)   0.995                                                     ND                    ND
  ZAP-70 (\> 20%)     1.400 (0.702-2.792)   0.340                                                     ND                    ND
  *TP53* disruption   4.049 (2.013-8.147)   \< 0.001^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^   2.900 (1.327-6.338)   0.008^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^
  *IGHV* unmutated    3.514 (1.690-7.307)   0.001^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^      2.835 (1.239-6.489)   0.014^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^
  AFR ≤ 9.7           3.648 (1.667-7.985)   0.001^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^      3.467 (1.536-7.824)   0.003^[a)](#tfn2-crt-2018-358){ref-type="table-fn"}^

HR, hazard ratio; CI, confidence interval; ND, not done; β2-MG, β2-microglobulin; *TP53*, tumor protein 53; *IGHV*, immunoglobulin heavy variable-region; AFR, albumin-to-fibrinogen ratio.

Statistically significant.
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